DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer

Our study addresses the issue of the clinical reliability of three candidate DPYD and one UGT single nucleotide polymorphisms in predicting 5-fluorouracil- and irinotecan-related adverse events. To this purpose, we took advantage of a large cohort of metastatic colorectal cancer patients treated wit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Cremolini, Chiara, Del Re, Marzia, Antoniotti, Carlotta, Lonardi, Sara, Bergamo, Francesca, Loupakis, Fotios, Borelli, Beatrice, Marmorino, Federica, Citi, Valentina, Cortesi, Enrico, Moretto, Roberto, Ronzoni, Monica, Tomasello, Gianluca, Zaniboni, Alberto, Racca, Patrizia, Buonadonna, Angela, Allegrini, Giacomo, Ricci, Vincenzo, Di Donato, Samantha, Zagonel, Vittorina, Boni, Luca, Falcone, Alfredo, Danesi, Romano
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5814264/
https://ncbi.nlm.nih.gov/pubmed/29487697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23559
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados